It may be possible to specifically reduce tumor viability while preserving normal cells by targeting mitochondrial ATP synthesis, changing dynamics through Drp1 or fusion protein modulation, or interfering with mitochondrial trafficking and positioning. This evidence concerns the gene DNM1L and neoplasm.